Carefully observe for signs & symptoms of bleeding; discontinue use if severe haemorrhage occurs. May cause mucosal bleedings & anaemia in long term use. Perform clinical surveillance, lab testing of Hb hematocrit to detect occult bleeding. Monitor signs of bleeding complications & anaemia after initiation of treatment in patients at increased risk of bleeding. Not recommended in concomitant use w/ systemic azole antimycotics eg, ketoconazole, itraconazole, voriconazole & posaconazole or HIV protease inhibitors eg, ritonavir. Concomitant treatment w/ drugs affecting haemostasis eg, NSAIDs, acetylsalicylic acid, platelet aggregation inhibitors or other antithrombotic agents. Consider appropriate prophylaxis for patients at risk of ulcerative GI disease. Patients w/ increased bleeding risk eg, congenital or acquired bleeding disorders, uncontrolled or severe arterial HTN, other GI disease w/o active ulceration that can lead to bleeding complications eg, inflammatory bowel disease, oesophagitis, gastritis & GERD, vascular retinopathy, bronchiectasis or history of pulmonary bleeding. Not recommended in patients w/ prosthetic heart valves. Discontinue use 24 hr prior to an invasive procedure or surgical intervention & restart as soon as adequate haemostasis has been established. Increased risk of epidural or spinal haematoma resulting to long-term or permanent paralysis when neuraxial (epidural/spinal) anaesth or spinal/epidural puncture is performed especially w/ use of indwelling epidural catheters or concomitant use of drugs affecting haemostasis & traumatic or repeated epidural or spinal puncture; monitor for signs & symptoms of neurological impairment eg, leg numbness or weakness, bowel or bladder dysfunction. Do not w/draw epidural catheter <18 hr after last administration; administer next dose ≥6 hr after removal of catheter; delay treatment for 24 hr if traumatic puncture occurs. Do not use in patients w/ rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. Not recommended as an alternative to unfractionated heparin in patients w/ pulmonary embolism who are haemodynamically unstable or may receive thrombolysis or pulmonary embolectomy. May impair ability to drive & operate machinery. Increased bleeding risk in severe renal impairment (CrCl <30 mL/min); caution in use in CrCl 15-30 mL/min; not recommended in CrCl <15 mL/min. Not recommended for childn <18 yr. Increased haemorrhagic risk in the elderly.